Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study

ConclusionsThese results show that survival of patients with severe COVID-19 is higher in those treated with tocilizumab than in those not treated and that tocilizumab's effect adds to that of steroids administered to non-intubated patients with COVID-19 during the first 48  h of presenting with respiratory failure despite oxygen therapy. Randomised controlled studies are needed to confirm these results.Trial registrationEuropean Union electronic Register of Post-Authorization Studies (EU PAS Register) identifier, EUPAS34415
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research